

ROS-Responsive mPEG–PCL Nanoparticles for Co-Delivery of Paclitaxel Prodrug and R848 in Synergistic Chemo-Immunotherapy

Qi Zhang ^a, Luyao Wang ^b, Zhaofan Yang ^c, Hao Meng ^b, Shixian Lv ^{c,*}, Linlin Liu ^{b,*}

^a *Department of Radiotherapy, The Second Hospital of Jilin University, Changchun, Jilin, 130041, China*

^b *Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, China*

^c *Key Laboratory of Polymer Chemistry and Physics of Ministry of Education, School of Materials Science and Engineering, Peking University, Beijing, 100871, China*




Figure S2. ¹H NMR spectrum of PTX-PBE.




Figure S3. HPLC analysis of PTX release triggered by 100 μM H_2O_2 .




Figure S4 *In vivo* fluorescence imaging of tumors at different time points (3, 6, 12, and 24 h) after intravenous injection of PLNPs.




Figure S5. Size distribution and photo image (inset) of Cy5-labeled PLNPs.




Figure S6. Quantitative data of apoptosis and necrosis rates of CT26 cells treated with free PTX-PBE, free R848 and PLNPs for 24 h.




Figure S7. Gating strategy for activated DCs.